Journal of Hematology & Oncology

Papers
(The median citation count of Journal of Hematology & Oncology is 17. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)
ArticleCitations
1-year survival in haemophagocytic lymphohistiocytosis: a nationwide cohort study from England 2003–2018492
Novel natural killer cell-based therapies for hematologic and solid malignancies: latest updates from ASCO 2024486
The small inhibitor WM-1119 effectively targets KAT6A-rearranged AML, but not KMT2A-rearranged AML, despite shared KAT6 genetic dependency484
HRAS is a therapeutic target in malignant chemo-resistant adenomyoepithelioma of the breast471
Identification of restrictive molecules involved in oncolytic virotherapy using genome-wide CRISPR screening465
Retraction Note: m6A mRNA methylation initiated by METTL3 directly promotes YAP translation and increases YAP activity by regulating the MALAT1-miR-1914-3p-YAP axis to induce NSCLC drug resistance and407
Mapping the cell therapy landscape: insights into clinical trials and regulatory advances in China392
WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associ363
KRAS mutation detection by liquid biopsy for pancreatic ductal adenocarcinoma356
The Association of Agent Orange Exposure with the progression of monoclonal gammopathy of undetermined significance to multiple myeloma: a population-based study of Vietnam War Era Veterans338
Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial330
Comprehensive molecular characterization of lung tumors implicates AKT and MYC signaling in adenocarcinoma to squamous cell transdifferentiation305
Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies303
CAR-T therapy alters synthesis of platelet-activating factor in multiple myeloma patients290
Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy280
Proteasome inhibition enhances oncolytic reovirus therapy in multiple myeloma independently of its direct cytotoxic effects277
Cancer vaccines: current status and future directions276
Landscape of biallelic DNMT3A mutant myeloid neoplasms261
Evidence of SARS-CoV-2 spike protein on retrieved thrombi from COVID-19 patients256
Modulating tumor infiltrating myeloid cells to enhance bispecific antibody-driven T cell infiltration and anti-tumor response248
Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2233
Integrated proteogenomic analysis revealed the metabolic heterogeneity in noncancerous liver tissues of patients with hepatocellular carcinoma227
Comparative analysis of cancer cell responses to targeted radionuclide therapy (TRT) and external beam radiotherapy (EBRT)221
Personalized nanovaccines for treating solid cancer metastases219
Overcome the challenge for intratumoral injection of STING agonist for pancreatic cancer by systemic administration214
NBAS, a gene involved in cytotoxic degranulation, is recurrently mutated in pediatric hemophagocytic lymphohistiocytosis213
Super-enhancer hijacking LINC01977 promotes malignancy of early-stage lung adenocarcinoma addicted to the canonical TGF-β/SMAD3 pathway193
Targeting CD47 for cancer immunotherapy187
Efficacy and safety of CPX-351 versus 7 + 3 chemotherapy by European LeukemiaNet 2017 risk subgroups in older adults with newly diagnosed, high-risk/secondary AML: post hoc analysis of a randomized, p184
Long noncoding RNA Smyca coactivates TGF-β/Smad and Myc pathways to drive tumor progression180
Hypoxia-induced exosomal circPDK1 promotes pancreatic cancer glycolysis via c-myc activation by modulating miR-628-3p/BPTF axis and degrading BIN1177
Cancer-associated fibroblast-specific lncRNA LINC01614 enhances glutamine uptake in lung adenocarcinoma164
Epigenetic regulation of diverse cell death modalities in cancer: a focus on pyroptosis, ferroptosis, cuproptosis, and disulfidptosis163
Ferroptosis: principles and significance in health and disease163
Hypertension and incident cardiovascular events after next-generation BTKi therapy initiation161
Toll-like receptors and toll-like receptor-targeted immunotherapy against glioma160
IL-15-secreting CAR natural killer cells directed toward the pan-cancer target CD70 eliminate both cancer cells and cancer-associated fibroblasts159
A novel lncRNA ROPM-mediated lipid metabolism governs breast cancer stem cell properties159
Recent advances in therapeutic strategies for non-small cell lung cancer155
Outcomes of patients with acute myeloid leukemia and bone marrow fibrosis154
Similar outcomes following non-first-degree and first-degree related donor haploidentical hematopoietic cell transplantation for acute leukemia patients in complete remission: a study from the Global 152
Correction: The long and short non-coding RNAs modulating EZH2 signaling in cancer149
Unraveling the roles and mechanisms of mitochondrial translation in normal and malignant hematopoiesis146
Targeted degradation of extracellular proteins: state of the art and diversity of degrader designs139
Identifying long-term survivors and those at higher or lower risk of relapse among patients with cytogenetically normal acute myeloid leukemia using a high-dimensional mixture cure model139
Small RNA modifications: regulatory molecules and potential applications137
The developing landscape of combinatorial therapies of immune checkpoint blockade with DNA damage repair inhibitors for the treatment of breast and ovarian cancers136
Non-invasive diagnosis of esophageal cancer by a simplified circulating cell-free DNA methylation assay targeting OTOP2 and KCNA3: a double-blinded, multicenter, prospective study134
3D chromatin architecture and transcription regulation in cancer132
Emerging strategies in targeting tumor-resident myeloid cells for cancer immunotherapy131
Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient?129
Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation127
Kynurenine derivative 3-HAA is an agonist ligand for transcription factor YY1125
Treatment with soluble CD24 attenuates COVID-19-associated systemic immunopathology124
Therapeutic roles of mesenchymal stem cell-derived extracellular vesicles in cancer123
Development of a novel combined nomogram model integrating deep learning-pathomics, radiomics and immunoscore to predict postoperative outcome of colorectal cancer lung metastasis patients120
First-in-human phase I study of CLL-1 CAR-T cells in adults with relapsed/refractory acute myeloid leukemia119
Recent advances in targeted strategies for triple-negative breast cancer118
A single-cell transcriptomic map of the murine and human multiple myeloma immune microenvironment across disease stages117
Osteosarcoma with cell-cycle and fibroblast growth factor genomic alterations: case report of Molecular Tumor Board combination strategy resulting in long-term exceptional response117
Development and validation of the post-CAR prognostic index for large B-cell lymphoma patients after CAR-T progression in third or later line treatment117
Recent advances in sarcoma therapy: new agents, strategies and predictive biomarkers115
Correction: Non-invasive diagnosis of esophageal cancer by a simplified circulating cell-free DNA methylation assay targeting OTOP2 and KCNA3: a double-blinded, multicenter, prospective study111
COVID-19 in pediatric cancer patients is associated with treatment interruptions but not with short-term mortality: a Polish national study110
Asciminib add-on to imatinib demonstrates sustained high rates of ongoing therapy and deep molecular responses with prolonged follow-up in the ASC4MORE study109
A single-cell and spatially resolved atlas of human osteosarcomas109
hUC-EVs-ATO reduce the severity of acute GVHD by resetting inflammatory macrophages toward the M2 phenotype109
Genotype–phenotype associations within the Li-Fraumeni spectrum: a report from the German Registry108
Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure107
Treatment outcomes for newly diagnosed, treatment-naïve TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis107
A proteolysis-targeting chimera molecule selectively degrades ENL and inhibits malignant gene expression and tumor growth107
Novel potent molecular glue degraders against broad range of hematological cancer cell lines via multiple neosubstrates degradation106
Methyltransferase-like proteins in cancer biology and potential therapeutic targeting105
GAS6-based CAR-T cells exhibit potent antitumor activity against pancreatic cancer105
Deciphering mechanisms of immune escape to inform immunotherapeutic strategies in multiple myeloma104
LCN2 secreted by tissue-infiltrating neutrophils induces the ferroptosis and wasting of adipose and muscle tissues in lung cancer cachexia104
Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies100
Targeting cuproptosis for cancer therapy: mechanistic insights and clinical perspectives99
Fibrinogen-like protein 1 (FGL1): the next immune checkpoint target99
Proteasome inhibition enhances the anti-leukemic efficacy of chimeric antigen receptor (CAR) expressing NK cells against acute myeloid leukemia98
Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts98
HLA alleles associated with asparaginase hypersensitivity in Chinese children96
Chemo-free treatment of adult patients with Ph-positive acute lymphoblastic leukemia: latest updates from the 2023 ASH annual meeting96
Preclinical evaluation of combination nemtabrutinib and venetoclax in chronic lymphocytic leukemia93
Correction: Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee93
Metabolic landscapes in sarcomas92
Circular RNAs: characteristics, biogenesis, mechanisms and functions in liver cancer92
Electrostatic anti-CD33-antibody–protamine nanocarriers as platform for a targeted treatment of acute myeloid leukemia90
Innate immune mediator, Interleukin-1 receptor accessory protein (IL1RAP), is expressed and pro-tumorigenic in pancreatic cancer90
The functional and clinical roles of liquid biopsy in patient-derived models88
Targeting Claudin-18.2 for cancer therapy: updates from 2024 ASCO annual meeting87
Prognostic and therapeutic implications of measurable residual disease in acute myeloid leukemia87
Iparomlimab (QL1604) in patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) unresectable or metastatic solid tumors: a pivotal, single-arm, multicenter, phase II 87
Echinomycin as a promising therapeutic agent against KSHV-related malignancies84
Worked to the bone: antibody-based conditioning as the future of transplant biology84
JMJD4-demethylated RIG-I prevents hepatic steatosis and carcinogenesis84
A clinical study of autologous chimeric antigen receptor macrophage targeting mesothelin shows safety in ovarian cancer therapy83
C3G promotes bone marrow adipocyte expansion and hematopoietic regeneration after myeloablation by enhancing megakaryocyte niche function83
LncRNA Snhg6 regulates the differentiation of MDSCs by regulating the ubiquitination of EZH282
Tucidinostat plus pediatric-inspired chemotherapy for newly diagnosed adult ETP-ALL/LBL: a single-arm, phase 2 trial82
The roles of GTPase-activating proteins in regulated cell death and tumor immunity82
CD20 xCD3 bispecific antibodies for large B cell lymphoma: latest updates from 2024 ASH annual meeting82
Cancer-associated fibroblast heterogeneity is associated with organ-specific metastasis in pancreatic ductal adenocarcinoma80
Gastric cancer treatment: recent progress and future perspectives79
Challenges and new technologies in adoptive cell therapy79
Clinical experiences with venetoclax and other pro-apoptotic agents in lymphoid malignancies: lessons from monotherapy and chemotherapy combination79
New immunotherapy strategies for patients with sarcomas: highlights from the 2023 ASCO annual meeting78
Intratumor heterogeneity: the hidden barrier to immunotherapy against MSI tumors from the perspective of IFN-γ signaling and tumor-infiltrating lymphocytes75
Lenvatinib and immune-checkpoint inhibitors in hepatocellular carcinoma: mechanistic insights, clinical efficacy, and future perspectives74
Targeting extracellular matrix stiffness and mechanotransducers to improve cancer therapy73
Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives72
The long and short non-coding RNAs modulating EZH2 signaling in cancer69
Long-term survival with donor CD19 CAR-T cell treatment for relapsed patients after allogeneic hematopietic stem cell transplantation67
GVHD occurrence does not reduce AML relapse following PTCy-based haploidentical transplantation: a study from the ALWP of the EBMT67
Genomic characterization of AML with aberrations of chromosome 7: a multinational cohort of 519 patients66
Targeting regulated cell death (RCD) with small-molecule compounds in triple-negative breast cancer: a revisited perspective from molecular mechanisms to targeted therapies66
m6A regulators as predictive biomarkers for chemotherapy benefit and potential therapeutic targets for overcoming chemotherapy resistance in small-cell lung cancer66
Targeting GPRC5D for multiple myeloma therapy66
Reduced-dose chemotherapy and blinatumomab as induction treatment for newly diagnosed Ph-negative B-cell precursor acute lymphoblastic leukemia: a phase 2 trial66
First-in-human phase I/Ib study of QL1706 (PSB205), a bifunctional PD1/CTLA4 dual blocker, in patients with advanced solid tumors66
RAS signaling in carcinogenesis, cancer therapy and resistance mechanisms65
Amplification of spatially isolated adenosine pathway by tumor–macrophage interaction induces anti-PD1 resistance in hepatocellular carcinoma64
SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders63
LncRNA-PACERR induces pro-tumour macrophages via interacting with miR-671-3p and m6A-reader IGF2BP2 in pancreatic ductal adenocarcinoma63
Applications of single-cell sequencing in cancer research: progress and perspectives61
Metabolic reprogramming in the tumor microenvironment of liver cancer61
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation60
METTL16 promotes liver cancer stem cell self-renewal via controlling ribosome biogenesis and mRNA translation60
Mesenchymal stem/stromal cells in cancer therapy60
Correction: Immunosenescence: a key player in cancer development60
Universal immunotherapeutic strategy for hepatocellular carcinoma with exosome vaccines that engage adaptive and innate immune responses60
Homogeneously high expression of CD32b makes it a potential target for CAR-T therapy for chronic lymphocytic leukemia59
Broadly applicable TCR-based therapy for multiple myeloma targeting the immunoglobulin J chain59
Large-scale real-life analysis of survival and usage of therapies in multiple myeloma58
Correction: Large-scale real-life analysis of survival and usage of therapies in multiple myeloma57
Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study56
Considerations for the design of antibody drug conjugates (ADCs) for clinical development: lessons learned56
Blockade of checkpoint receptor PVRIG unleashes anti-tumor immunity of NK cells in murine and human solid tumors56
Correction : LINC01123, a c-Myc-activated long non-coding RNA, promotes proliferation and aerobic glycolysis of non-small cell lung cancer through miR-199a-5p/c-Myc axis56
Treatment of myelodysplastic syndromes in the era of precision medicine and immunomodulatory drugs: a focus on higher-risk disease55
Momelotinib: an emerging treatment for myelofibrosis patients with anemia55
Nanomaterials-driven in situ vaccination: a novel frontier in tumor immunotherapy54
Replicon RNA vaccines: design, delivery, and immunogenicity in infectious diseases and cancer54
Elevated plasma levels of IL-6 and MCP-1 selectively identify CML patients who better sustain molecular remission after TKI withdrawal54
Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee53
Mesenchymal stromal cells plus basiliximab, calcineurin inhibitor as treatment of steroid-resistant acute graft-versus-host disease: a multicenter, randomized, phase 3, open-label trial53
Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study52
Advances in targeting histone deacetylase for treatment of solid tumors52
The cGAS‒STING pathway in cancer immunity: mechanisms, challenges, and therapeutic implications51
A practical approach on the classifications of myeloid neoplasms and acute leukemia: WHO and ICC51
Circular RNA circHERC4 as a novel oncogenic driver to promote tumor metastasis via the miR-556-5p/CTBP2/E-cadherin axis in colorectal cancer51
Emerging strategies to target RAS signaling in human cancer therapy50
Precision oncology in AML: validation of the prognostic value of the knowledge bank approach and suggestions for improvement49
Safety and efficacy of amulirafusp alfa (IMM0306), a fusion protein of CD20 monoclonal antibody with the CD47 binding domain of SIRPα, in patients with relapsed or refractory B-cell non-Hodgkin lympho49
Advances in CAR-T cell therapy for hematologic and solid malignancies: latest updates from 2024 ESMO Congress49
Retraction Note: AMLnet, A deep-learning pipeline for the differential diagnosis of acute myeloid leukemia from bone marrow smears49
High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status49
Immune checkpoint of B7-H3 in cancer: from immunology to clinical immunotherapy49
Myeloid-like tumor hybrid cells in bone marrow promote progression of prostate cancer bone metastasis49
Correction to: HLA-A2.1-restricted ECM1-derived epitope LA through DC cross-activation priming CD8+ T and NK cells: a novel therapeutic tumour vaccine49
Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the EPICOVIDEHA registry48
Targeting ERRα promotes cytotoxic effects against acute myeloid leukemia through suppressing mitochondrial oxidative phosphorylation48
C3aR costimulation enhances the antitumor efficacy of CAR-T cell therapy through Th17 expansion and memory T cell induction47
Development and application of nanomaterials, nanotechnology and nanomedicine for treating hematological malignancies47
Crosstalk among m6A RNA methylation, hypoxia and metabolic reprogramming in TME: from immunosuppressive microenvironment to clinical application46
Non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary versus de novo AML in first complete remission: a study from the ALWP/EBMT46
The relationship between expression of PD-L1 and HIF-1α in glioma cells under hypoxia46
Global status and attributable risk factors of breast, cervical, ovarian, and uterine cancers from 1990 to 202146
Novel clinical risk stratification and treatment strategies in relapsed/refractory peripheral T-cell lymphoma46
Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/245
Prognostic landscape of mitochondrial genome in myelodysplastic syndrome after stem-cell transplantation45
A novel role of lysophosphatidic acid (LPA) in human myeloma resistance to proteasome inhibitors45
Germline biallelic BRCA2 pathogenic variants and medulloblastoma: an international cohort study45
Safety and preliminary efficacy of the Gam-COVID-Vac vaccine and outcomes of SARS-CoV-2 infection in Russian patients with genitourinary malignancies44
Matched related transplantation versus immunosuppressive therapy plus eltrombopag for first-line treatment of severe aplastic anemia: a multicenter, prospective study44
Functions, mechanisms, and therapeutic implications of METTL14 in human cancer43
Optimizing CAR-T cell therapy for solid tumors: current challenges and potential strategies42
Matching-adjusted indirect treatment comparison of liso-cel versus axi-cel in relapsed or refractory large B cell lymphoma42
Integrated clinical and proteomic-based model for diagnostic and prognostic prediction in pRCC42
Targeting inflammation as cancer therapy42
Correction: Dual inhibition of IGF-IR and ALK as an effective strategy to eradicate NPM-ALK+ T-cell lymphoma41
Lipid metabolic reprogramming in tumor microenvironment: from mechanisms to therapeutics41
The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades41
Post-transplant cyclophosphamide alters immune signatures and leads to impaired T cell reconstitution in allogeneic hematopoietic stem cell transplant41
Phase II trial of daratumumab with DCEP in relapsed/refractory multiple myeloma patients with extramedullary disease41
Reprogramming T cell differentiation and exhaustion in CAR-T cell therapy41
Quality-adjusted Time Without Symptoms of disease or Toxicity (Q-TWiST) analysis of CPX-351 versus 7 + 3 in older adults with newly diagnosed high-risk/secondary AML40
KAI1(CD82) is a key molecule to control angiogenesis and switch angiogenic milieu to quiescent state40
Spatial imaging unlocks the potential of charting multiple myeloma and extramedullary disease40
Bispecific antibody-activated T cells enhance NK cell-mediated antibody-dependent cellular cytotoxicity40
Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: latest updates from ASCO 2023 Annual Meeting40
Multiscale protein networks systematically identify aberrant protein interactions and oncogenic regulators in seven cancer types40
Menin inhibitors for the treatment of acute myeloid leukemia: challenges and opportunities ahead39
BCMA-targeted therapies for multiple myeloma: latest updates from 2024 ASH annual meeting39
Elraglusib (9-ING-41), a selective small-molecule inhibitor of glycogen synthase kinase-3 beta, reduces expression of immune checkpoint molecules PD-1, TIGIT and LAG-3 and enhances CD8+ T cell cytolyt39
The consensus from The Chinese Society of Hematology on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation: 2021 update38
Regimens combining radiation and immunotherapy for cancer: latest updates from 2024 ASCO Annual Meeting38
Wnt/β-catenin signaling pathway in carcinogenesis and cancer therapy37
RNA demethylase ALKBH5 in cancer: from mechanisms to therapeutic potential37
Impaired neutralisation of SARS-CoV-2 delta variant in vaccinated patients with B cell chronic lymphocytic leukaemia36
Novel strategies for cancer immunotherapy: counter-immunoediting therapy36
CD20 × CD3 bispecific antibodies for lymphoma therapy: latest updates from ASCO 2023 annual meeting36
Correction: Phase IB part of LOC-R01, a LOC network non-comparative randomized phase IB/II study testing R-MPV in combination with escalating doses of lenalidomide or ibrutinib for newly diagnosed pri36
Engineered CRO-CD7 CAR-NK cells derived from pluripotent stem cells avoid fratricide and efficiently suppress human T-cell malignancies36
Small extracellular vesicle non-coding RNAs in pancreatic cancer: molecular mechanisms and clinical implications35
A novel tRNA-derived fragment tRF-3022b modulates cell apoptosis and M2 macrophage polarization via binding to cytokines in colorectal cancer35
Anti-TGF-β/PD-L1 bispecific antibody synergizes with radiotherapy to enhance antitumor immunity and mitigate radiation-induced pulmonary fibrosis35
Synergistic efficacy of simultaneous anti-TGF-β/VEGF bispecific antibody and PD-1 blockade in cancer therapy34
Heterodimerization of T cell engaging bispecific antibodies to enhance specificity against pancreatic ductal adenocarcinoma34
Genitourinary cancers updates: highlights from ASCO 202333
Novel ADCs and combination therapy in urothelial carcinoma: latest updates from the 2023 ASCO-GU Cancers Symposium33
Disruption of the sorcin‒PAX5 protein‒protein interaction induces ferroptosis by promoting the FBXL12-mediated ubiquitination of ALDH1A1 in pancreatic cancer33
Oral eltanexor treatment of patients with higher-risk myelodysplastic syndrome refractory to hypomethylating agents33
Therapeutic implications of cancer gene amplifications without mRNA overexpression: silence may not be golden33
Global burden of cancer and associated risk factors in 204 countries and territories, 1980–2021: a systematic analysis for the GBD 202132
Leveraging CD16 fusion receptors to remodel the immune response for enhancing anti-tumor immunotherapy in iPSC-derived NK cells32
Homologous recombination deficiency (HRD) can predict the therapeutic outcomes of immuno-neoadjuvant therapy in NSCLC patients32
Involvement of inflammasomes in tumor microenvironment and tumor therapies32
Prostate cancer multiparametric magnetic resonance imaging visibility is a tumor-intrinsic phenomena32
Randomized phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced soft-tissue sarcoma32
CD19 CAR-T in relapsed t(8;21) AML: a single-center prospective phase II clinical trial32
Treatment-induced arteriolar revascularization and miR-126 enhancement in bone marrow niche protect leukemic stem cells in AML31
Evolving therapeutic landscape in follicular lymphoma: a look at emerging and investigational therapies30
The R-RAS2 GTPase is a signaling hub in triple-negative breast cancer cell metabolism and metastatic behavior30
Unraveling the triad of hypoxia, cancer cell stemness, and drug resistance30
Non-canonical small noncoding RNAs in the plasma extracellular vesicles as novel biomarkers in gastric cancer29
CXCL13 chemokine is a novel player in multiple myeloma osteolytic microenvironment, M2 macrophage polarization, and tumor progression29
Targeting STAT3-VISTA axis to suppress tumor aggression and burden in acute myeloid leukemia28
Remodeling of anti-tumor immunity with antibodies targeting a p53 mutant28
PD-1 blockade immunotherapy as a successful rescue treatment for disseminated adenovirus infection after allogeneic hematopoietic stem cell transplantation28
A novel tRNA-derived fragment AS-tDR-007333 promotes the malignancy of NSCLC via the HSPB1/MED29 and ELK4/MED29 axes28
Incidence, mortality, risk factors, and trends for Hodgkin lymphoma: a global data analysis28
Recent progress on vascular endothelial growth factor receptor inhibitors with dual targeting capabilities for tumor therapy28
Recent advances in therapeutic strategies for triple-negative breast cancer28
CircRNA-CREIT inhibits stress granule assembly and overcomes doxorubicin resistance in TNBC by destabilizing PKR28
Consensus, debate, and prospective on pancreatic cancer treatments28
Liquid biopsy: current technology and clinical applications28
Therapeutic strategies in METex14 skipping mutated non-small cell lung cancer27
PARP1-MGMT complex underpins pathway crosstalk in O6-methylguanine repair27
Venetoclax Combined with Azacitidine and Homoharringtonine in Relapsed/Refractory AML: A Multicenter, Phase 2 Trial27
Correction: The cGAS‒STING pathway in cancer immunity: mechanisms, challenges, and therapeutic implications27
The mitochondrial unfolded protein response (UPRmt): shielding against toxicity to mitochondria in cancer27
Lipid-based nanosystems: the next generation of cancer immune therapy27
Harnessing immunotherapy for brain metastases: insights into tumor–brain microenvironment interactions and emerging treatment modalities27
Protein degradation technology: a strategic paradigm shift in drug discovery27
The global, regional, and national burden of cancer among adolescents and young adults in 204 countries and territories, 1990–2019: a population-based study26
Development and characterization of NILK-2301, a novel CEACAM5xCD3 κλ bispecific antibody for immunotherapy of CEACAM5-expressing cancers26
Spatial architecture of the immune microenvironment orchestrates tumor immunity and therapeutic response26
CRISPR/Cas9-mediated deletion of Interleukin-30 suppresses IGF1 and CXCL5 and boosts SOCS3 reducing prostate cancer growth and mortality26
CAR-NK cell therapy for hematological malignancies: recent updates from ASH 202226
0.062341928482056